Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1

Season 6 Episode 28  ·  Feb 17, 2022, 07:55 PM

Headliner
Share
Subscribe

Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tumors, as well as the parallel studies ARTACUS and CERPASS, which are further exploring the agent.

Share
Subscribe
Next
Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
by OncLive® On Air